- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | NewcelX prices $1.55M share offering at $3.29 to fund diabetes program | 1 | Seeking Alpha | ||
| Mo | NewcelX Ltd.: NewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to Market | 3 | GlobeNewswire (USA) | ||
| NEWCELX Aktie jetzt für 0€ handeln | |||||
| 04.11. | NewcelX To Acquire Mazindol Assets From REA Holdings | 5 | RTTNews | ||
| 04.11. | NewcelX Ltd.: NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments | 5 | GlobeNewswire (USA) | ||
| 04.11. | NewcelX Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 28.09. | NewcelX Ltd.: NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes | 1 | GlobeNewswire (USA) | ||
| 18.09. | NLS Pharmaceutics GAAP EPS of -$0.96 | 1 | Seeking Alpha | ||
| 18.09. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 31.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 31.07. | NewcelX Ltd.: NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing | 1 | GlobeNewswire (USA) | ||
| 15.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.07. | Laidlaw initiates NewcelX stock with buy rating on diabetes therapy | 1 | Investing.com | ||
| 08.07. | NewcelX beruft Diabetes-Forscher Ricordi in den wissenschaftlichen Beirat | 1 | Investing.com Deutsch | ||
| 08.07. | NewcelX appoints diabetes researcher Ricordi to advisory board | 1 | Investing.com | ||
| 08.07. | NewcelX Ltd.: NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board | 2 | GlobeNewswire (USA) | ||
| 08.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.07. | NewcelX Ltd.: NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes | 589 | GlobeNewswire (Europe) | ZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. ("NewcelX"; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful completion... ► Artikel lesen | |
| 30.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,554 | -0,89 % | Valneva meldet positive Phase-2-Daten für Shigellen-Impfstoff | Valneva hat mit seinem Impfstoffkandidaten S4V2 gegen Shigellose positive Ergebnisse aus zwei klinischen Phase-2-Studien erzielt. In einer US-amerikanischen Studie mit kontrollierter Infektion gesunder... ► Artikel lesen | |
| NOVAVAX | 7,770 | +0,39 % | Novavax: Zahlen über Plan - was Anleger jetzt prüfen sollten | ||
| PALATIN TECHNOLOGIES | 6,230 | 0,00 % | Palatin Sinks Ahead of Q1 Results | ||
| OCUGEN | 0,755 | +0,53 % | Ocugen: Zahlen schlagen Erwartungen, aber die Aktie bleibt unter Druck - Deal im Fokus | ||
| VIVORYON THERAPEUTICS | 0,766 | -0,52 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,319 | +3,57 % | 200 Prozent Ausbeute, 1 geplanter GMP-Partner: Warum NurExone und Made Scientific die Exosomenproduktion skalieren wollen | ||
| SAREPTA THERAPEUTICS | 14,540 | -0,27 % | Sarepta Therapeutics auf Guggenheim-Konferenz: Starker Cashflow finanziert breite Entwicklungspipeline | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,734 | -2,25 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,390 | +4,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| MYRIAD GENETICS | 5,232 | +2,15 % | Stephens raises Myriad Genetics stock price target on revenue beat | ||
| MANNKIND | 3,716 | -0,72 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,130 | -9,60 % | Onco-Innovations Limited: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF) (Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| NOVOCURE | 10,570 | -1,49 % | JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer | Novocure (Nasdaq: NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields)... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 5,500 | -2,65 % | Ocular Therapeutix outlines Q4 2026 AXPAXLI NDA plan with $530.6M cash runway into 2028 | ||
| TRAWS PHARMA | 0,275 | +9,56 % | Traws Pharma Advances Oral COVID-19, Monthly Flu Antiviral Toward Next Milestones |
NEWCELX LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,38 % bei einem Aktienkurs von 2,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWCELX LTD finden Sie auf Wallstreet Online.